Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-06-16 Sale |
2023-06-16 4:00 pm |
Prometheus Biosciences Inc. | RXDX | Stenhouse Mark Chief Operating Officer |
26,754 | $0 | $0 | 0 (Indirect Direct) |
View |
| 2021-03-16 Purchase |
2021-03-16 9:49 pm |
Prometheus Biosciences Inc. | RXDX | Stenhouse Mark Chief Operating Officer |
14,000 | $19 | $266,000 | 14,000 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-05-23 Option Award |
2024-05-24 7:18 pm |
N/A 2034-05-22 |
Phathom Pharmaceuticals Inc. | PHAT | Stenhouse Mark Director |
28,000 | $0 | 37,000 (Direct) |
View |
| 2023-06-01 Other |
2023-06-02 6:57 pm |
N/A N/A |
Prometheus Biosciences Inc. | RXDX | Stenhouse Mark Chief Operating Officer |
14,000 | $0 | 54,708 (Direct) |
View |
| 2023-05-25 Option Award |
2023-05-30 7:01 pm |
N/A 2033-05-24 |
Phathom Pharmaceuticals Inc. | PHAT | Stenhouse Mark Director |
24,000 | $0 | 24,000 (Direct) |
View |
| 2022-12-09 Option Award |
2022-12-13 8:38 pm |
N/A 2032-12-08 |
Prometheus Biosciences Inc. | RXDX | Stenhouse Mark Chief Operating Officer |
43,896 | $0 | 60,527 (Direct) |
View |
| 2022-05-25 Option Award |
2022-05-27 4:50 pm |
N/A 2032-05-24 |
Phathom Pharmaceuticals Inc. | PHAT | Stenhouse Mark Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2022-05-20 Option Award |
2022-05-20 7:15 pm |
2025-05-20 2032-05-19 |
Prometheus Biosciences Inc. | RXDX | Stenhouse Mark Chief Operating Officer |
86,582 | $0 | 86,582 (Direct) |
View |
| 2021-11-14 Option Award |
2021-11-16 9:10 pm |
N/A 2031-11-13 |
Prometheus Biosciences Inc. | RXDX | Stenhouse Mark Chief Operating Officer |
70,371 | $0 | 70,371 (Direct) |
View |
| 2021-05-21 Option Award |
2021-05-24 5:44 pm |
N/A 2031-05-20 |
Phathom Pharmaceuticals Inc. | PHAT | Stenhouse Mark Director |
12,500 | $0 | 12,500 (Direct) |
View |
Ownership |
2021-03-11 9:29 pm |
2021-02-04 2028-05-22 |
Prometheus Biosciences Inc. | RXDX | Stenhouse Mark Chief Operating Officer |
0 | $0 | 280,000 (Direct) |
View |